MedTrace Logo

GLP_1 RA Ultrasound Study

NCT06581120 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-11-07

No results posted yet for this study

Summary

The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.

Conditions

  • Glucagon Like Peptide-1 (GLP-1
  • Delayed Gastric Emptying
  • Risk of Aspiration
  • Diabetes
  • Morbid Obesity

Interventions

DRUG

Glucagon-Like Peptide-1 receptor agonists

GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.

DIAGNOSTIC_TEST

Point of Care Gastric Ultrasound

A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Eligibility

Min Age
10 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-08
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06581120 on ClinicalTrials.gov